The Center is actively participating in clinical trials of new therapies that may improve our patients’ quality of life and better control disease activity. Current, active clinical trials are listed below.
Current – Active Studies
1) Sildenafil in Early Pulmonary Vascular Disease in Systemic Sclerosis. This study seeks to evaluate whether treatment with sildenafil in scleroderma patients with minimally elevated pulmonary arterial pressures (21-24 mmHg) improves cardiopulmonary outcomes.
We are actively enrolling in this study. This study is being led by our colleagues in the Johns Hopkins Pulmonary Hypertension Center.
2) A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Phase 3 Study Evaluating the Safety and Efficacy of Intravenous Iloprost in Subjects With Systemic Sclerosis Experiencing Symptomatic Digital Ischemic Episodes (AURORA Study).
We are actively enrolling in this study.
3) An open-label extension trial to assess the long term safety of nintedanib in patients with ‘Systemic Sclerosis associated
Interstitial Lung Disease’ (SSc-ILD).
Enrollment is closed.
4) A Phase 2 Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of Ifetroban in Patients With Diffuse Cutaneous Systemic Sclerosis or Systemic Sclerosis-Associated Pulmonary Arterial Hypertension.
We are actively enrolling in this study.
5) A Phase 2, Randomized, Placebo-controlled, Double-blind, Open-label Extension Multicenter Study to Evaluate the Efficacy and Safety of KD025 in Subjects with Diffuse Cutaneous Systemic Sclerosis.
We are actively enrolling in this study.
